Alternating carboplatin and doxorubicin as adjunctive chemotherapy to amputation or limb-sparing surgery in the treatment of appendicular osteosarcoma in dogs

Michael S Kent, Adam Strom, Cheryl A. London, Bernard Seguin

Research output: Contribution to journalArticle

63 Scopus citations

Abstract

Thirty-two dogs with appendicular osteosarcoma treated by amputation or limb sparing had adjuvant chemotherapy of alternating doses of carboplatin (300 mg/m2 IV) and doxorubicin (30 mg/m2 IV) every 21 days for a total of 3 cycles. Efficacy, toxicity, and previously identified prognostic factors for osteosarcoma were evaluated. The median progression free survival was 227 days (range 180-274), and the median overall survival was 320 days (range 153-487). The 1-year survival rate was 48%, and the 2-year survival rate was 18%. Age, sex, surgical procedure, and alkaline phosphatase activity above the reference ranges were not prognostic for survival. There was minimal toxicity associated with the chemotherapy. This protocol could be useful for the adjuvant treatment of appendicular osteosarcoma of dogs.

Original languageEnglish (US)
Pages (from-to)540-544
Number of pages5
JournalJournal of Veterinary Internal Medicine
Volume18
Issue number4
DOIs
StatePublished - Jul 2004

Keywords

  • Cancer
  • Canine
  • Neoplasia
  • Primary bone tumor

ASJC Scopus subject areas

  • veterinary(all)

Fingerprint Dive into the research topics of 'Alternating carboplatin and doxorubicin as adjunctive chemotherapy to amputation or limb-sparing surgery in the treatment of appendicular osteosarcoma in dogs'. Together they form a unique fingerprint.

  • Cite this